Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 1 to 10 of 2039

TitleReference numberPublishedLast updated
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)TA1154
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentTA1153
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesityTA1152
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancerTA1150
Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal)TA1151
Digital technologies to support self-management of asthma: early-use assessmentHTG778
Acne vulgaris: managementNG198
Digital technologies for managing non-specific low back pain: early value assessmentHTG712
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelomaTA1149
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and overTA1147

Results per page

  1. 10
  2. 25
  3. 50
  4. All